CN101102781B - 亚氯酸盐治疗神经变性疾病 - Google Patents

亚氯酸盐治疗神经变性疾病 Download PDF

Info

Publication number
CN101102781B
CN101102781B CN2005800037236A CN200580003723A CN101102781B CN 101102781 B CN101102781 B CN 101102781B CN 2005800037236 A CN2005800037236 A CN 2005800037236A CN 200580003723 A CN200580003723 A CN 200580003723A CN 101102781 B CN101102781 B CN 101102781B
Authority
CN
China
Prior art keywords
als
disease
patients
cells
chlorite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800037236A
Other languages
English (en)
Chinese (zh)
Other versions
CN101102781A (zh
Inventor
M·S·麦格拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34860199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101102781(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Priority to CN201110317862.3A priority Critical patent/CN102423318B/zh
Publication of CN101102781A publication Critical patent/CN101102781A/zh
Application granted granted Critical
Publication of CN101102781B publication Critical patent/CN101102781B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2005800037236A 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病 Expired - Lifetime CN101102781B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110317862.3A CN102423318B (zh) 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54157604P 2004-02-03 2004-02-03
US60/541,576 2004-02-03
PCT/US2005/002469 WO2005076819A2 (en) 2004-02-03 2005-01-25 Chlorite in the treatment of neurodegenerative disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201110317862.3A Division CN102423318B (zh) 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病

Publications (2)

Publication Number Publication Date
CN101102781A CN101102781A (zh) 2008-01-09
CN101102781B true CN101102781B (zh) 2012-06-20

Family

ID=34860199

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2005800037236A Expired - Lifetime CN101102781B (zh) 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病
CN201110317862.3A Expired - Lifetime CN102423318B (zh) 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201110317862.3A Expired - Lifetime CN102423318B (zh) 2004-02-03 2005-01-25 亚氯酸盐治疗神经变性疾病

Country Status (7)

Country Link
US (5) US7105183B2 (https=)
EP (2) EP1711191B1 (https=)
JP (3) JP5072367B2 (https=)
CN (2) CN101102781B (https=)
AU (1) AU2005213300B2 (https=)
CA (2) CA2554511C (https=)
WO (1) WO2005076819A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005510524A (ja) * 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
EP1810030A1 (en) * 2004-07-16 2007-07-25 Gyros Patent Ab Sequential method
KR101637140B1 (ko) 2005-05-09 2016-07-06 테라노스, 인코포레이티드 현장진료 유체 시스템 및 그 용도
CA2617637C (en) * 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
JP5371443B2 (ja) 2005-12-22 2013-12-18 ニューラルタス ファーマシューティカルズ，インコーポレイテッド 亜塩素酸塩製剤、およびこの調製の方法と利用
AU2013234421B2 (en) * 2005-12-22 2015-08-27 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US8007999B2 (en) 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
US20100040574A1 (en) * 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
US20080113391A1 (en) 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
EP2285409B1 (en) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
BR112012002333A2 (pt) * 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
EP3859746B1 (en) 2009-10-19 2024-10-16 Labrador Diagnostics LLC Integrated health data capture and analysis system
WO2011111043A1 (en) * 2010-03-10 2011-09-15 Yeda Research And Development Co. Ltd Cellular blood markers for early diagnosis of als and for als progression
EP2582391B1 (en) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis treatment
PL2605771T3 (pl) * 2010-08-16 2018-10-31 Allergan, Inc. Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN108404127B (zh) 2011-09-23 2025-12-12 埃克斯生物科技公司 恶病质治疗
WO2013093891A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP3142674A4 (en) * 2014-05-16 2018-01-17 Neuraltus Pharmaceuticals, Inc. Methods and compositions for treatment of macrophage-related disorders
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
WO2017079161A2 (en) 2015-11-02 2017-05-11 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
EP4412624A4 (en) 2021-10-04 2025-08-20 Neuvivo Inc TREATMENT METHODS FOR ALS PATIENTS
GB2637227A (en) * 2022-05-19 2025-07-16 Neuvivo Inc Biomarkers for neurogenerative disease
WO2025014800A2 (en) * 2023-07-07 2025-01-16 The Regents Of The University Of California Chlorite uses for stem cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213389A1 (de) * 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
DE3515745A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US5051414A (en) * 1989-08-03 1991-09-24 Dupont Merck Pharmaceutical Company Inhibition of HIV and other retroviruses by polyoxoanions
DE4208828A1 (de) * 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US6099855A (en) * 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5877222A (en) * 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
WO1999017787A2 (en) * 1997-10-06 1999-04-15 Oxo Chemie Ag Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
JP2001078775A (ja) * 1999-09-14 2001-03-27 Kokuritsu Seishin Shinkei Center マクロファージ機能調節剤
WO2001040517A2 (en) * 1999-11-30 2001-06-07 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
US6685754B2 (en) 2001-03-06 2004-02-03 Alchemix Corporation Method for the production of hydrogen-containing gaseous mixtures
JP2005510524A (ja) * 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease

Also Published As

Publication number Publication date
US20120295296A1 (en) 2012-11-22
EP1711191A4 (en) 2008-12-17
JP5797083B2 (ja) 2015-10-21
CN101102781A (zh) 2008-01-09
EP1711191B1 (en) 2014-03-19
US9364501B2 (en) 2016-06-14
US8029826B2 (en) 2011-10-04
AU2005213300A1 (en) 2005-08-25
US20170065634A1 (en) 2017-03-09
US20110053186A1 (en) 2011-03-03
CA2838392A1 (en) 2005-08-25
CA2838392C (en) 2017-04-04
WO2005076819A3 (en) 2006-04-13
AU2005213300B2 (en) 2011-06-16
CN102423318B (zh) 2015-09-09
CA2554511C (en) 2016-01-19
EP2574342A1 (en) 2013-04-03
JP5072367B2 (ja) 2012-11-14
CN102423318A (zh) 2012-04-25
JP2015205901A (ja) 2015-11-19
JP2007520554A (ja) 2007-07-26
WO2005076819A2 (en) 2005-08-25
EP2574342B1 (en) 2018-03-07
US7105183B2 (en) 2006-09-12
US20060159775A1 (en) 2006-07-20
CA2554511A1 (en) 2005-08-25
EP1711191A2 (en) 2006-10-18
US20050181068A1 (en) 2005-08-18
JP2012067110A (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
CN101102781B (zh) 亚氯酸盐治疗神经变性疾病
MacLeod et al. Frequency and morbidity of severe hypoglycaemia in insulin‐treated diabetic patients
Beekman et al. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients
US20170106017A1 (en) Methods and compositions for treatment of macrophage-related disorders
Téllez-Zenteno et al. Prognostic factors of thymectomy in patients with myasthenia gravis: a cohort of 132 patients
AU2014203207B2 (en) Chlorite in the treatment of neurodegenerative disease
Dominguez et al. Long term outcomes in patients with anti-DPPX autoimmunity
Barohn et al. Soluble terminal complement components in human myasthenia gravis
Almurakshi et al. Secondary syphilis presents as palmoplantar Hyperpigmented Maculopapules: a case report
Eurelings et al. Sural nerve T cells in demyelinating polyneuropathy associated with monoclonal gammopathy
Haupt et al. Severity of symptoms and rate of progression in Alzheimer's disease: a comparison of cases with early and late onset
Frenkel et al. Perinatal HIV infection and AIDS
Emami et al. Journal of Clinical Images and Medical Case Reports
Viola What is Alzheimer’s disease?
Oostra et al. Mitochondrial DNA analysis as a diagnostic tool in singleton cases of Leber's hereditary optic neuropathy
Heyes et al. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific
Underwood Robert R. Kierland, Paul A. O'Leary,* and
Kierland et al. later with penicillin alone. So the results of treatment herein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20120620